GO:0002291 T cell activation via T cell receptor contact with antigen bound to MHC molecule on antigen presenting cell: Mechanism, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0002291 describes the process by which a mature or immature T cell changes its morphology and behavior after its T cell receptor (TCR) binds a specific antigen presented by an MHC molecule on an antigen-presenting cell (APC), initiating or perpetuating an immune response.
• This process is the central event in adaptive immunity, enabling T cells to recognize foreign or altered self-antigens and mount a targeted response.
• TCR engagement by peptide-MHC complexes triggers intracellular signaling cascades that lead to T cell proliferation, cytokine production, and effector differentiation.
• The minimal requirements for stimulating unprimed CD8+ T cells can be defined using transfected Drosophila cells expressing MHC and costimulatory molecules, demonstrating the power of reductionist systems.
• Lipopeptide antigens can also activate T cells through TCR contact with antigen bound to MHC-like molecules, expanding the range of ligands that trigger this GO term.
• Dysregulation of this activation process underlies autoimmune diseases, immunodeficiencies, and cancer immune evasion, making it a key target for therapeutic intervention.
Description
T cell activation via T cell receptor contact with antigen bound to MHC molecule on antigen presenting cell (GO:0002291) is a fundamental biological process in adaptive immunity. It refers to the change in morphology and behavior of a mature or immature T cell that occurs when its T cell receptor (TCR) specifically recognizes an antigen bound to an MHC molecule on the surface of an antigen-presenting cell (APC). This interaction is the cornerstone of the immune system's ability to distinguish self from non-self and to respond to pathogens, tumors, and allergens. The process leads to the initiation or perpetuation of an immune response, encompassing T cell proliferation, cytokine secretion, and differentiation into effector and memory subsets. Researchers study this term to understand how T cells are primed, how immune tolerance is broken in autoimmunity, and how to harness T cell responses for cancer immunotherapy and vaccine design. The QuickGO definition emphasizes the morphological and behavioral changes of the T cell resulting from this specific receptor-ligand engagement, distinguishing it from other forms of T cell activation such as those induced by cytokines or mitogens. Experimental models, including transfected Drosophila cells expressing defined MHC and costimulatory molecules, have been instrumental in dissecting the minimal requirements for stimulating unprimed CD8+ T cells, providing a reductionist platform to study this process. Additionally, non-classical antigens such as lipopeptides can activate T cells through TCR contact with antigen bound to MHC-like molecules, further broadening the scope of this GO term.
T cell activation via T cell receptor contact with antigen bound to MHC molecule on antigen presenting cell At A Glance
| GO ID | GO:0002291 |
|---|---|
| GO term | T cell activation via T cell receptor contact with antigen bound to MHC molecule on antigen presenting cell |
| Ontology | biological_process |
| Synonym | T-cell activation via T cell receptor contact with antigen bound to MHC molecule on antigen presenting cell; T lymphocyte activation via T cell receptor contact with antigen bound to MHC molecule on antigen presenting cell; T-lymphocyte activation via T cell receptor contact with antigen bound to MHC molecule on antigen presenting cell |
| Major function | Initiation and perpetuation of adaptive immune responses through T cell recognition of peptide-MHC complexes on APCs |
| Definition source | QuickGO definition |
| Related cellular components | T cell receptor complex, MHC protein complex, immunological synapse |
| Related molecular functions | Antigen binding, MHC protein binding, signaling receptor activity |
| Key cell types | T cells (CD4+ and CD8+), antigen-presenting cells (dendritic cells, macrophages, B cells) |
What Is GO:0002291?
GO:0002291 is defined as the change in morphology and behavior of a mature or immature T cell resulting from exposure to an antigen for which its T cell receptor is specific, bound to an MHC molecule on an antigen presenting cell, leading to the initiation or perpetuation of an immune response. In simpler terms, it is the process by which a T cell becomes activated after its TCR recognizes a specific antigen presented by an MHC molecule on another cell, triggering a cascade of events that ultimately leads to an immune response.
Why Is T cell activation via T cell receptor contact with antigen bound to MHC molecule on antigen presenting cell Important in Cell Biology?
GO:0002291 is critically important because it represents the central checkpoint of adaptive immunity, determining whether a T cell will respond to a given antigen. This process is essential for host defense against pathogens, immune surveillance of tumors, and the establishment of immunological memory. Its dysregulation can lead to a spectrum of diseases, including autoimmune disorders, immunodeficiency, and cancer. Understanding the molecular and cellular requirements for this activation process is fundamental for developing vaccines, immunotherapies, and treatments for immune-related diseases.
• Central to adaptive immunity: enables T cells to recognize and respond to specific antigens presented by APCs.
• Required for T cell proliferation, cytokine production, and differentiation into effector and memory cells.
• Dysregulation causes autoimmune diseases such as contact allergy and other inflammatory conditions.
• Impaired activation leads to immunodeficiency and increased susceptibility to infections.
• Key target for cancer immunotherapy, including checkpoint inhibitors and adoptive T cell transfer.
• Essential for vaccine development, as vaccines aim to prime T cells via this activation pathway.
• Lipopeptide antigens can activate T cells through this process, expanding its relevance to non-peptide antigens.
• Minimal requirements for activation can be studied using transfected Drosophila cells, aiding mechanistic dissection.
• Provides a basis for understanding T cell tolerance and autoimmunity.
• Enables the design of synthetic antigen-presenting systems for research and therapy.
What Happens During T cell activation via T cell receptor contact with antigen bound to MHC molecule on antigen presenting cell?
Antigen recognition by the T cell receptor
In simple terms: The T cell uses its receptor to recognize a specific antigen presented by another cell.
The process begins when a T cell encounters an antigen-presenting cell (APC) displaying a peptide antigen bound to an MHC molecule. The T cell receptor (TCR) specifically binds to this peptide-MHC complex, providing the first signal for activation. This interaction is highly specific and is the defining event of GO:0002291. The TCR recognizes the antigen in the context of MHC, ensuring that T cells respond only to antigens presented by self-MHC molecules, a phenomenon known as MHC restriction. The minimal requirements for this recognition can be studied using transfected Drosophila cells expressing MHC and costimulatory molecules, which can stimulate unprimed CD8+ T cells.
Costimulation and second signals
In simple terms: The T cell needs a second signal from the antigen-presenting cell to become fully activated.
In addition to TCR engagement, full T cell activation requires costimulatory signals provided by the APC. These signals are delivered through interactions between costimulatory molecules on the APC and their receptors on the T cell, such as CD80/CD86 binding to CD28. Without costimulation, TCR engagement can lead to anergy or tolerance rather than activation. The requirement for costimulation can be bypassed in reductionist systems using transfected Drosophila cells expressing defined costimulatory molecules, which have been used to define the minimal requirements for stimulating unprimed CD8+ T cells. This second signal ensures that T cells are activated only in the appropriate context, such as during infection or inflammation.
Intracellular signaling and morphological changes
In simple terms: Signals from the receptor travel inside the T cell, causing it to change shape and behavior.
Upon TCR engagement and costimulation, intracellular signaling cascades are initiated. These involve phosphorylation of immunoreceptor tyrosine-based activation motifs (ITAMs) in the CD3 chains of the TCR complex, recruitment of kinases such as ZAP-70, and activation of downstream pathways including the MAPK, PI3K, and calcium-calcineurin pathways. These signals lead to changes in gene expression, cytoskeletal reorganization, and morphological changes that are characteristic of activated T cells. The T cell may polarize, form an immunological synapse with the APC, and begin to secrete cytokines such as IL-2, which drives proliferation. The definition of GO:0002291 explicitly includes these changes in morphology and behavior.
Initiation and perpetuation of the immune response
In simple terms: The activated T cell then multiplies and coordinates an immune response.
The ultimate outcome of this activation process is the initiation or perpetuation of an immune response. Activated T cells proliferate, differentiate into effector subsets (e.g., Th1, Th2, Th17, cytotoxic T lymphocytes), and migrate to sites of infection or inflammation. They also provide help to B cells and activate other immune cells. Some activated T cells become memory T cells, providing long-lasting immunity. The process is perpetuated by positive feedback loops, including cytokine secretion and further T cell recruitment. This GO term encompasses the entire cascade from initial TCR contact to the functional consequences of activation. Additionally, lipopeptide antigens can trigger this process through TCR contact with antigen bound to MHC-like molecules, demonstrating the versatility of T cell activation.
Key Genes Involved in GO:0002291 T cell activation via T cell receptor contact with antigen bound to MHC molecule on antigen presenting cell
The following genes and proteins are central to the process of T cell activation via T cell receptor contact with antigen bound to MHC molecule on antigen presenting cell.
| Gene | Major Role | Research Relevance |
|---|---|---|
| CD3D | Component of the TCR-CD3 complex, required for signal transduction | Knockout leads to defective T cell development and activation |
| CD3E | Component of the TCR-CD3 complex, involved in ITAM signaling | Mutations cause immunodeficiency; target for functional studies |
| CD3G | Component of the TCR-CD3 complex | Defects impair T cell activation; model for immunodeficiency |
| CD4 | Co-receptor for MHC class II, enhances TCR signaling in helper T cells | Knockout reduces CD4+ T cell responses; target for HIV research |
| CD8A | Co-receptor for MHC class I, enhances TCR signaling in cytotoxic T cells | Knockout impairs CD8+ T cell activation; used in cytotoxicity studies |
| LCK | Src-family kinase that phosphorylates CD3 ITAMs | Knockout causes severe T cell developmental block |
| ZAP70 | Syk-family kinase recruited to phosphorylated ITAMs | Mutations cause immunodeficiency; key signaling node |
| LAT | Adaptor protein that nucleates signaling complexes | Knockout abrogates T cell activation |
| CD28 | Costimulatory receptor for CD80/CD86 | Knockout reduces T cell activation; target for immunotherapy |
| CD80 | Ligand for CD28 on APCs | Overexpression enhances T cell activation in models |
| CD86 | Ligand for CD28 on APCs | Overexpression enhances T cell activation in models |
| HLA-A | MHC class I molecule presenting endogenous peptides | Knockout affects CD8+ T cell activation; used in antigen presentation studies |
| HLA-DRA | MHC class II molecule presenting exogenous peptides | Knockout affects CD4+ T cell activation; used in autoimmunity research |
| B2M | Beta-2-microglobulin, required for MHC class I stability | Knockout abolishes CD8+ T cell activation; common in cancer models |
| ITK | Tec-family kinase downstream of TCR | Knockout impairs T cell activation and cytokine production |
| PLCG1 | Phospholipase C gamma 1, generates IP3 and DAG | Knockout blocks calcium flux and T cell activation |
| NFATC1 | Transcription factor activated by calcineurin | Knockout impairs cytokine production and T cell differentiation |
How Is T cell activation via T cell receptor contact with antigen bound to MHC molecule on antigen presenting cell Regulated?
The process of T cell activation via TCR contact with antigen bound to MHC on APCs is tightly regulated at multiple levels. Positive regulation involves costimulatory signals through CD28 and cytokines such as IL-2, which promote activation and proliferation. Negative regulation is mediated by immune checkpoint molecules such as CTLA-4 and PD-1, which dampen TCR signaling to prevent autoimmunity and limit tissue damage. Additionally, the strength and duration of TCR signaling, the density of peptide-MHC complexes, and the presence of costimulatory or coinhibitory ligands all influence the outcome of activation. The transcription factor NFAT, activated by calcium-calcineurin signaling, plays a key role in regulating cytokine gene expression. The process can also be modulated by lipopeptide antigens that engage TCRs in an MHC-like context, adding another layer of regulation. Understanding these regulatory mechanisms is essential for therapeutic manipulation of T cell responses.
T cell activation via T cell receptor contact with antigen bound to MHC molecule on antigen presenting cell and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| CD3E | Immunodeficiency | Knockout mouse or cell line; point mutations to mimic patient variants |
| ZAP70 | Immunodeficiency | Knock-in of patient mutations; knockout for signaling studies |
| HLA-DRA | Autoimmunity (e.g., rheumatoid arthritis) | Overexpression or knockout in APC lines; antigen presentation assays |
| B2M | Cancer immune evasion | Knockout in tumor cells to abolish MHC class I presentation |
| CD28 | Autoimmunity and transplant rejection | Knockout or overexpression in T cells; costimulation blockade studies |
Autoimmune diseases and contact allergy
Dysregulated T cell activation via TCR contact with antigen bound to MHC on APCs can lead to autoimmune diseases, where T cells mistakenly attack self-tissues. Contact allergy is a classic example, where T cells become activated against environmental allergens presented by APCs in the skin, leading to inflammatory responses. The process of T cell activation is central to the pathogenesis of many autoimmune conditions, including rheumatoid arthritis, multiple sclerosis, and type 1 diabetes. Understanding the triggers and regulatory checkpoints of this activation process is crucial for developing therapies that selectively suppress harmful T cell responses.
Immunodeficiency
Defects in the molecules that mediate T cell activation, such as CD3 chains, ZAP-70, or MHC molecules, can result in severe immunodeficiency. For example, mutations in CD3E or ZAP70 cause impaired T cell development and function, leading to increased susceptibility to infections. These conditions highlight the non-redundant roles of the TCR signaling machinery in host defense. Research using knockout and knock-in models of these genes has been instrumental in defining the minimal requirements for T cell activation, including studies with transfected Drosophila cells that express defined MHC and costimulatory molecules.
Cancer and immunotherapy
T cell activation via TCR contact with antigen bound to MHC on APCs is the foundation of cancer immunotherapy. Checkpoint inhibitors, such as anti-CTLA-4 and anti-PD-1 antibodies, work by blocking negative regulators of this activation process, thereby enhancing T cell responses against tumors. Adoptive T cell therapies, including CAR-T cells, rely on engineering T cells to recognize tumor antigens in an MHC-dependent or independent manner. Understanding the molecular details of this GO term is essential for improving the efficacy of immunotherapies and overcoming resistance mechanisms. Additionally, lipopeptide antigens can activate T cells through this pathway, offering potential for novel vaccine strategies.
From T cell activation via T cell receptor contact with antigen bound to MHC molecule on antigen presenting cell-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| What is the minimal requirement for stimulating unprimed CD8+ T cells? | Transfected Drosophila cells expressing MHC and costimulatory molecules |
| How does a specific point mutation in ZAP70 affect T cell activation? | Point-mutation knock-in cell lines or mice |
| What is the role of CD3E in TCR signaling? | Knockout cell lines or mice |
| How does overexpression of CD80 affect T cell activation? | Overexpression cell models in APCs |
| Can a candidate gene regulate T cell activation? | CRISPR knockout screen followed by functional readout |
| How does a tagged version of LAT behave in live cells? | Tagged knock-in (e.g., GFP) for imaging |
How to Study the T cell activation via T cell receptor contact with antigen bound to MHC molecule on antigen presenting cell Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Flow cytometry | Surface activation markers (CD69, CD25) and intracellular cytokines | Quantifying T cell activation in mixed lymphocyte reactions |
| Calcium flux assay | Intracellular calcium mobilization | Assessing proximal TCR signaling |
| RNA-seq | Global transcriptional changes | Identifying gene expression programs induced by activation |
| Cytokine bead array | Secretion of multiple cytokines (e.g., IL-2, IFN-gamma) | Profiling effector functions |
| Confocal microscopy | Immunological synapse formation and protein localization | Studying spatial organization of signaling |
| CRISPR knockout screen | Identification of genes required for activation | Functional genomics of T cell activation |
| Phospho-proteomics | Phosphorylation events downstream of TCR | Mapping signaling networks |
| Tetramer staining | Antigen-specific TCR frequency | Detecting rare antigen-specific T cells |
Flow cytometry and activation markers
Flow cytometry is widely used to measure T cell activation by detecting surface markers such as CD69, CD25, and CD44, as well as intracellular cytokines. This method allows researchers to quantify the percentage of activated T cells after co-culture with APCs presenting specific antigens. It is a standard readout for assessing the functional outcome of GO:0002291.
Calcium flux and signaling assays
Calcium flux assays using fluorescent dyes (e.g., Indo-1 or Fluo-4) measure the increase in intracellular calcium that occurs rapidly after TCR engagement. This is a direct readout of proximal TCR signaling and is often used to study the function of signaling molecules such as PLCG1 and ITK. These assays can be performed in cell lines or primary T cells.
Transcriptomics and cytokine profiling
RNA sequencing and cytokine bead arrays are used to profile gene expression changes and cytokine secretion following T cell activation. These methods provide a global view of the transcriptional programs induced by TCR engagement, including the upregulation of activation markers and effector molecules. They are valuable for identifying novel regulators of this process.
Imaging of the immunological synapse
Advanced imaging techniques, such as confocal and super-resolution microscopy, allow visualization of the immunological synapse formed between a T cell and an APC. This reveals the spatial organization of TCRs, costimulatory molecules, and signaling proteins during activation. Such studies have been instrumental in understanding the morphological changes that define GO:0002291.
How CRISPR Can Be Used to Study GO:0002291 T cell activation via T cell receptor contact with antigen bound to MHC molecule on antigen presenting cell
Knockout
CRISPR knockout is used to delete genes involved in T cell activation to study their loss-of-function phenotypes. For example, knocking out CD3E, LCK, or ZAP70 in T cell lines or primary T cells abolishes TCR signaling and activation, confirming their essential roles. Knockout screens can identify novel regulators of GO:0002291 by assessing activation markers after gene disruption.
Point Mutation
Point mutations can be introduced using CRISPR base editing or homology-directed repair to model patient-specific variants or to dissect domain functions. For instance, point mutations in ZAP70 that cause immunodeficiency can be knocked into cell lines to study their impact on T cell activation. This approach provides insights into the structure-function relationships of signaling molecules.
Knock-in
Knock-in of reporter genes (e.g., GFP) or epitope tags into endogenous loci allows real-time monitoring of protein expression and localization during T cell activation. Tagged knock-in of LAT or CD3E can be used to study their dynamics at the immunological synapse. Knock-in of specific MHC alleles can also be used to study antigen presentation.
Overexpression
Overexpression of costimulatory molecules such as CD80 or CD86 in APCs can enhance T cell activation in co-culture experiments. Conversely, overexpression of inhibitory molecules like CTLA-4 can suppress activation. These models are useful for studying the dose-dependent effects of signaling components on GO:0002291.
How EDITGENE Supports T cell activation via T cell receptor contact with antigen bound to MHC molecule on antigen presenting cell Research
Researchers studying T cell activation via T cell receptor contact with antigen bound to MHC molecule on antigen presenting cell-related genes often need to determine whether a candidate gene is causally involved in this process. EDITGENE provides a comprehensive suite of CRISPR-based services to enable precise genetic manipulation in relevant cell models, from knockout to knock-in and library screening.
Contact EDITGENE today to design your custom CRISPR model for T cell activation via T cell receptor contact with antigen bound to MHC molecule on antigen presenting cell research.
Related Products
| Product name | Cat.No. | Species | Gene ID | |
|---|---|---|---|---|
| Trem2 Knockout BV-2 Cell Line | EDC07598 | Mouse | 83433 | Details Get a Quote |
| ICAM1 Knockout HEK293 Cell Line | EDJ-KQ93 | Human | 3383 | Details Get a Quote |
| TREM2 Knockout HEK293 Cell Line | EDJ-KQ1140 | Human | 54209 | Details Get a Quote |
| ITGAL Knockout HEK293 Cell Line | EDJ-KQ1350 | Human | 3683 | Details Get a Quote |
| PLXNA1 Knockout HEK293 Cell Line | EDJ-KQ5485 | Human | 5361 | Details Get a Quote |
| TYROBP Knockout HEK293 Cell Line | EDJ-KQ5985 | Human | 7305 | Details Get a Quote |
| SEMA6D Knockout HEK293 Cell Line | EDJ-KQ15223 | Human | 80031 | Details Get a Quote |
| TREM2 Overexpression BV-2 Stable Cell Line | EDC90074 | Mouse | 54209 | Details Get a Quote |
| ICAM1 Knockout HCT 116 Cell Line | EDJ-KQ21079 | Human | 3383 | Details Get a Quote |
| ICAM1 Knockout HeLa Cell Line | EDJ-KQ21080 | Human | 3383 | Details Get a Quote |
| ICAM1 Knockout A-549 Cell Line | EDJ-KQ26288 | Human | 3383 | Details Get a Quote |
| PLXNA1 Knockout A-549 Cell Line | EDJ-KQ28708 | Human | 5361 | Details Get a Quote |
| PLXNA1 Knockout HCT 116 Cell Line | EDJ-KQ28709 | Human | 5361 | Details Get a Quote |
| PLXNA1 Knockout HeLa Cell Line | EDJ-KQ28710 | Human | 5361 | Details Get a Quote |
| TREM2 Knockout THP-1 Cell Line | EDJ-KZ61 | Human | 54209 | Details Get a Quote |
Displaying Records 1 To 15 Of 29 Records
Frequently Asked Questions About T cell activation via T cell receptor contact with antigen bound to MHC molecule on antigen presenting cell
What is GO:0002291?
GO:0002291 is a Gene Ontology biological process term that describes the change in morphology and behavior of a mature or immature T cell resulting from exposure to an antigen for which its T cell receptor is specific, bound to an MHC molecule on an antigen presenting cell, leading to the initiation or perpetuation of an immune response.
What genes are involved in T cell activation via T cell receptor contact with antigen bound to MHC molecule on antigen presenting cell?
Key genes include CD3D, CD3E, CD3G, CD4, CD8A, LCK, ZAP70, LAT, CD28, CD80, CD86, HLA-A, HLA-DRA, B2M, ITK, PLCG1, and NFATC1.
How does T cell activation via T cell receptor contact with antigen bound to MHC molecule on antigen presenting cell work?
The T cell receptor binds a specific peptide-MHC complex on an antigen-presenting cell, triggering intracellular signaling cascades that lead to changes in gene expression, morphology, and behavior, ultimately initiating or perpetuating an immune response.
What are the minimal requirements for stimulating unprimed CD8+ T cells?
Studies using transfected Drosophila cells expressing defined MHC and costimulatory molecules have helped define the minimal requirements for stimulating unprimed CD8+ T cells.
Can lipopeptide antigens activate T cells through this process?
Yes, lipopeptide antigens can activate T cells through TCR contact with antigen bound to MHC-like molecules, as reviewed in the context of T-cell activation by lipopeptide antigens.
What diseases are associated with dysregulation of GO:0002291?
Dysregulation can lead to autoimmune diseases such as contact allergy, immunodeficiencies, and cancer immune evasion.
How is T cell activation via T cell receptor contact with antigen bound to MHC molecule on antigen presenting cell studied?
Common methods include flow cytometry for activation markers, calcium flux assays, RNA-seq, cytokine profiling, and imaging of the immunological synapse.
What is the role of costimulation in this process?
Costimulation, such as CD28 binding to CD80/CD86, provides a second signal that is required for full T cell activation; without it, TCR engagement can lead to anergy.
What CRISPR models are available to study this process?
CRISPR knockout, point mutation, knock-in, and overexpression models can be generated in T cell lines or primary cells to study gene function in this activation process.
Why is GO:0002291 important for immunotherapy?
Understanding this process is essential for cancer immunotherapy, as checkpoint inhibitors and adoptive T cell therapies aim to enhance or modulate T cell activation against tumors.
Conclusion
GO:0002291, T cell activation via T cell receptor contact with antigen bound to MHC molecule on antigen presenting cell, is a cornerstone of adaptive immunity. It encompasses the molecular and cellular events that convert a resting T cell into an activated effector cell capable of orchestrating an immune response. Dysregulation of this process contributes to autoimmunity, immunodeficiency, and cancer, making it a prime target for therapeutic intervention. Continued research using advanced CRISPR models and functional genomics will further illuminate the mechanisms and enable the development of novel immunotherapies.
References
- 1. Schuler G. 1993. [Contact allergy].. Wien Klin Wochenschr 105(22):641-7 PMID: 8291258
- 2. Van Rhijn I et al.. 2005. T-cell activation by lipopeptide antigens.. Curr Opin Immunol 17(3):222-9 PMID: 15886110
- 3. Cai Z et al.. 1996. Transfected Drosophila cells as a probe for defining the minimal requirements for stimulating unprimed CD8+ T cells.. Proc Natl Acad Sci U S A 93(25):14736-41 PMID: 8962124
